<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">ploscomp</journal-id><journal-title-group><journal-title>PLoS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19756158</article-id><article-id pub-id-type="publisher-id">09-PLCB-RA-0420R2</article-id><article-id pub-id-type="doi">10.1371/journal.pcbi.1000498</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Biochemistry/Molecular Evolution</subject><subject>Biochemistry/Structural Genomics</subject><subject>Biotechnology/Bioengineering</subject><subject>Computational Biology</subject><subject>Computational Biology/Synthetic Biology</subject><subject>Oncology</subject></subj-group></article-categories><title-group><article-title>Predicting Positive p53 Cancer Rescue Regions Using Most Informative Positive (MIP) Active Learning</article-title><alt-title alt-title-type="running-head">Predicting Positive p53 Cancer Rescue Regions</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Danziger</surname><given-names>Samuel A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Baronio</surname><given-names>Roberta</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ho</surname><given-names>Lydia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hall</surname><given-names>Linda</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Salmon</surname><given-names>Kirsty</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hatfield</surname><given-names>G. Wesley</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kaiser</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lathrop</surname><given-names>Richard H.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Institute for Genomics and Bioinformatics, University of California, Irvine, Irvine, California, United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Biomedical Engineering, University of California, Irvine, Irvine, California, United States of America</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Department of Microbiology and Molecular Genetics, University of California, Irvine, Irvine, California, United States of America</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Department of Biological Chemistry, University of California, Irvine, Irvine, California, United States of America</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Department of Computer Science, University of California, Irvine, Irvine, California, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Briggs</surname><given-names>James M.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of Houston, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>pkaiser@uci.edu</email> (PK); <email>rickl@uci.edu</email> (RHL)</corresp><fn fn-type="con"><p>Conceived and designed the experiments: S. Danziger R. Baronio G. Hatfield P. Kaiser R. Lathrop. Performed the experiments: S. Danziger R. Baronio L. Ho L. Hall K. Salmon P. Kaiser. Analyzed the data: S. Danziger R. Baronio P. Kaiser R. Lathrop. Contributed reagents/materials/analysis tools: S. Danziger K. Salmon G. Hatfield P. Kaiser. Wrote the paper: S. Danziger P. Kaiser R. Lathrop.</p></fn></author-notes><pub-date pub-type="collection"><month>9</month><year>2009</year></pub-date><!-- Fake ppub added to accomodate plos workflow change from 03/2008 and 03/2009 --><pub-date pub-type="ppub"><month>9</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>4</day><month>9</month><year>2009</year></pub-date><volume>5</volume><issue>9</issue><elocation-id>e1000498</elocation-id><history><date date-type="received"><day>21</day><month>4</month><year>2009</year></date><date date-type="accepted"><day>4</day><month>8</month><year>2009</year></date></history><permissions><copyright-statement>Danziger et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><p>Many protein engineering problems involve finding mutations that produce proteins with a particular function. Computational active learning is an attractive approach to discover desired biological activities. Traditional active learning techniques have been optimized to iteratively improve classifier accuracy, not to quickly discover biologically significant results. We report here a novel active learning technique, Most Informative Positive (MIP), which is tailored to biological problems because it seeks novel and informative positive results. MIP active learning differs from traditional active learning methods in two ways: (1) it preferentially seeks Positive (functionally active) examples; and (2) it may be effectively extended to select gene regions suitable for high throughput combinatorial mutagenesis. We applied MIP to discover mutations in the tumor suppressor protein p53 that reactivate mutated p53 found in human cancers. This is an important biomedical goal because <italic>p53</italic> mutants have been implicated in half of all human cancers, and restoring active p53 in tumors leads to tumor regression. MIP found Positive (cancer rescue) p53 mutants <italic>in silico</italic> using 33&#x00025; fewer experiments than traditional non-MIP active learning, with only a minor decrease in classifier accuracy. Applying MIP to <italic>in vivo</italic> experimentation yielded immediate Positive results. Ten different p53 mutations found in human cancers were paired <italic>in silico</italic> with all possible single amino acid rescue mutations, from which MIP was used to select a Positive Region predicted to be enriched for p53 cancer rescue mutants. <italic>In vivo</italic> assays showed that the predicted Positive Region: (1) had significantly more (p&#x0003c;0.01) new strong cancer rescue mutants than control regions (Negative, and non-MIP active learning); (2) had slightly more new strong cancer rescue mutants than an Expert region selected for purely biological considerations; and (3) rescued for the first time the previously unrescuable p53 cancer mutant P152L.</p></abstract><abstract abstract-type="summary"><title>Author Summary</title><p>Engineering proteins to acquire or enhance a particular useful function is at the core of many biomedical problems. This paper presents Most Informative Positive (MIP) active learning, a novel integrated computational/biological approach designed to help guide biological discovery of novel and informative positive mutants. A classifier, together with modeled structure-based features, helps guide biological experiments and so accelerates protein engineering studies. MIP reduces the number of expensive biological experiments needed to achieve novel and informative positive results. We used the MIP method to discover novel p53 cancer rescue mutants. p53 is a tumor suppressor protein, and destructive p53 mutations have been implicated in half of all human cancers. Second-site cancer rescue mutations restore p53 activity and eventually may facilitate rational design of better cancer drugs. This paper shows that, even in the first round of in vivo experiments, MIP significantly increased the discovery rate of novel and informative positive mutants.</p></abstract><counts><page-count count="12"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Engineering existing proteins to change their properties <xref ref-type="bibr" rid="pcbi.1000498-Fersht1">&#x0005b;1&#x0005d;</xref>,<xref ref-type="bibr" rid="pcbi.1000498-Huston1">&#x0005b;2&#x0005d;</xref> is an important task with many applications as diverse as environmental protection, synthetic biomaterials, and pharmacology <xref ref-type="bibr" rid="pcbi.1000498-Danziger1">&#x0005b;3&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pcbi.1000498-Dantas1">&#x0005b;8&#x0005d;</xref>. Here we apply machine learning techniques to engineer the tumor suppressor protein p53. We choose where to mutate cancerous p53 to restore tumor suppressor function, using structure-based features derived from <italic>in silico</italic> protein homology models.</p><sec id="s1a"><title>Biology of p53 Cancer Rescue Mutants</title><p>The <italic>p53</italic> gene encodes a tumor suppressor protein that is a key cellular defense against cancer. p53 mutations occur in about 50&#x00025; of human cancers. The vast majority of these mutations are single point missense mutations in the <italic>p53</italic> core domain <xref ref-type="bibr" rid="pcbi.1000498-Brooks1">&#x0005b;9&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pcbi.1000498-Petitjean1">&#x0005b;12&#x0005d;</xref>. Thus, many human cancers express full-length p53 cancer mutants that lack tumor suppressor function. As demonstrated <italic>in vivo</italic>, p53 cancer mutants can be reactivated through intragenic second-site suppressor (&#x0201c;cancer rescue&#x0201d;) mutations <xref ref-type="bibr" rid="pcbi.1000498-Baroni1">&#x0005b;13&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pcbi.1000498-Otsuka1">&#x0005b;15&#x0005d;</xref>. Reactivated p53 holds great therapeutic promise because animal models have shown that reintroduction of active p53, even in advanced tumors, leads to tumor regression <xref ref-type="bibr" rid="pcbi.1000498-Sharpless1">&#x0005b;16&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pcbi.1000498-Xue1">&#x0005b;18&#x0005d;</xref>. Consequently, there have been many efforts to find small molecule drugs that mimic the cancer rescue effect of reactivating p53 and suppressing tumor growth <xref ref-type="bibr" rid="pcbi.1000498-Lain1">&#x0005b;19&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pcbi.1000498-Lambert1">&#x0005b;24&#x0005d;</xref>. Despite some promising discoveries in p53 in specific, and small molecule docking in general, these efforts are hampered by a limited understanding of the p53 mutation-structure-function relationship <xref ref-type="bibr" rid="pcbi.1000498-Kato1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pcbi.1000498-Martin1">&#x0005b;25&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pcbi.1000498-Cuff1">&#x0005b;28&#x0005d;</xref>. A larger and more diverse collection of cancer rescue mutations that reactivate p53 cancer mutants is therefore desired. Such a collection could lead to insight into general structural changes that can rescue p53 cancer mutants, and thereby facilitate rational drug design approaches by exploiting similar effects.</p><p>Several p53 cancer rescue mutants were identified previously by random mutagenesis in a region spanning amino acid residues 225&#x02013;241. A portion of this region (235,239, and 240) thus was empirically identified as a &#x0201c;Global Suppressor Motif&#x0201d;, the first p53 cancer rescue region <xref ref-type="bibr" rid="pcbi.1000498-Baroni1">&#x0005b;13&#x0005d;</xref>. The biological goal of this paper is to use computational techniques to discover novel p53 cancer rescue mutants and regions.</p></sec><sec id="s1b"><title>Integrated Experimental Design</title><p>The active learning paradigm was developed in the machine learning community to reduce the number of expensive examples that need to be acquired to build an accurate classifier <xref ref-type="bibr" rid="pcbi.1000498-Cohn1">&#x0005b;29&#x0005d;</xref>. Active learning typically starts with a small initial amount of labeled data. The initial data is used to determine a small informative set of unlabeled examples to label. Once labeled, these new examples are added to the pool of labeled data and a new unlabeled set is chosen. The process repeatedly labels new data until the classifier reaches some pre-determined criteria. Active learning methods increase the efficiency and cost effectiveness of the process by reducing the number of examples that need to be labeled. The active learning paradigm is readily applicable to biological experimentation, as it reduces the number of tedious and expensive experiments to be performed.</p><p>In a biological active learning paradigm, a computational classifier is trained with an initial set of examples labeled by direct experimentation. In the case of p53 cancer rescue mutants <xref ref-type="bibr" rid="pcbi.1000498-Danziger2">&#x0005b;4&#x0005d;</xref>, this initial set consists of empirically labeled p53 mutants. The computational classifier then predicts which mutants should next be labeled to most improve the classifier accuracy. These mutants are then made, labeled by biological assays, and added to the classifier. The cycle repeats, iteratively improving classifier accuracy and adding to the set of p53 mutants with known function. In this way, an optimum active learning classifier would adequately explore a mutant sequence space while using a minimum amount of expensive biological experimentation <xref ref-type="bibr" rid="pcbi.1000498-Danziger2">&#x0005b;4&#x0005d;</xref>.</p><p>It is important to note that in the context of biological experimentation, the slowest part of active learning is generally the biological experiments required to label the unknown examples. Therefore, any reference to speed in this paper refers to the number of expensive biological experiments (i.e. iterations of the active learning cycle) and not to computational speed. The computational goal of this paper is to provide and test computational methods that can discover gene regions wherein mutations produce proteins with a desired function, while requiring as few experiments as possible.</p></sec><sec id="s1c"><title>Traditional Active Learning</title><p>Here we present a formal description of the active learning problem. Notation is summarized in <xref ref-type="supplementary-material" rid="pcbi.1000498.s003">Text S1</xref>.</p><p>Let <inline-formula><inline-graphic xlink:href="pcbi.1000498.e001.jpg" mimetype="image"/></inline-formula> be the Total set of all examples under consideration. Each example mutant, <inline-formula><inline-graphic xlink:href="pcbi.1000498.e002.jpg" mimetype="image"/></inline-formula>, has a labeling function, <inline-formula><inline-graphic xlink:href="pcbi.1000498.e003.jpg" mimetype="image"/></inline-formula>, such that <inline-formula><inline-graphic xlink:href="pcbi.1000498.e004.jpg" mimetype="image"/></inline-formula>&#x0200a;&#x0003d;&#x0200a;Positive, Negative, or Unknown. During each active learning iteration, <inline-formula><inline-graphic xlink:href="pcbi.1000498.e005.jpg" mimetype="image"/></inline-formula>, <inline-formula><inline-graphic xlink:href="pcbi.1000498.e006.jpg" mimetype="image"/></inline-formula> is partitioned into two groups: (1) <inline-formula><inline-graphic xlink:href="pcbi.1000498.e007.jpg" mimetype="image"/></inline-formula>, examples with Known labels (i.e., <inline-formula><inline-graphic xlink:href="pcbi.1000498.e008.jpg" mimetype="image"/></inline-formula>&#x0200a;&#x0003d;&#x0200a;Positive or Negative); and (2) <inline-formula><inline-graphic xlink:href="pcbi.1000498.e009.jpg" mimetype="image"/></inline-formula>, examples with Unknown labels (i.e., <inline-formula><inline-graphic xlink:href="pcbi.1000498.e010.jpg" mimetype="image"/></inline-formula>&#x0200a;&#x0003d;&#x0200a;Unknown). A third set, <inline-formula><inline-graphic xlink:href="pcbi.1000498.e011.jpg" mimetype="image"/></inline-formula>, Chosen from <inline-formula><inline-graphic xlink:href="pcbi.1000498.e012.jpg" mimetype="image"/></inline-formula>, contains <inline-formula><inline-graphic xlink:href="pcbi.1000498.e013.jpg" mimetype="image"/></inline-formula> examples to be tested and labeled in this step.</p><p>During each iteration the classifier provides a decision function, <inline-formula><inline-graphic xlink:href="pcbi.1000498.e014.jpg" mimetype="image"/></inline-formula>, trained on the examples with a known label, <inline-formula><inline-graphic xlink:href="pcbi.1000498.e015.jpg" mimetype="image"/></inline-formula>. Each unlabeled example <inline-formula><inline-graphic xlink:href="pcbi.1000498.e016.jpg" mimetype="image"/></inline-formula> is predicted by the decision function <inline-formula><inline-graphic xlink:href="pcbi.1000498.e017.jpg" mimetype="image"/></inline-formula> to be Positive or Negative.</p><p>A score function, <inline-formula><inline-graphic xlink:href="pcbi.1000498.e018.jpg" mimetype="image"/></inline-formula>, ranks each example in <inline-formula><inline-graphic xlink:href="pcbi.1000498.e019.jpg" mimetype="image"/></inline-formula>. As a control, Random active learning assigns each mutant a random score. The <inline-formula><inline-graphic xlink:href="pcbi.1000498.e020.jpg" mimetype="image"/></inline-formula> highest ranked examples become <inline-formula><inline-graphic xlink:href="pcbi.1000498.e021.jpg" mimetype="image"/></inline-formula> and are then tested and labeled. <inline-formula><inline-graphic xlink:href="pcbi.1000498.e022.jpg" mimetype="image"/></inline-formula>is merged with <inline-formula><inline-graphic xlink:href="pcbi.1000498.e023.jpg" mimetype="image"/></inline-formula> to create<inline-formula><inline-graphic xlink:href="pcbi.1000498.e024.jpg" mimetype="image"/></inline-formula> and deleted from <inline-formula><inline-graphic xlink:href="pcbi.1000498.e025.jpg" mimetype="image"/></inline-formula>to create <inline-formula><inline-graphic xlink:href="pcbi.1000498.e026.jpg" mimetype="image"/></inline-formula>.</p><p>In the case of the p53 cancer rescue mutants here, each example <inline-formula><inline-graphic xlink:href="pcbi.1000498.e027.jpg" mimetype="image"/></inline-formula>is a p53 mutant. <inline-formula><inline-graphic xlink:href="pcbi.1000498.e028.jpg" mimetype="image"/></inline-formula>&#x0200a;&#x0003d;&#x0200a;Positive if and only if mutant <inline-formula><inline-graphic xlink:href="pcbi.1000498.e029.jpg" mimetype="image"/></inline-formula>exhibits wild-type like p53 transcription activator activity.</p></sec><sec id="s1d"><title>Structure of this Paper</title><p>The <xref ref-type="sec" rid="s2">Methods</xref> section presents a description of active learning, the MIP paradigm, computational evaluation methods, and the biological experimental design. The <xref ref-type="sec" rid="s3">Results</xref> section shows <italic>in silico</italic> results indicating the computational techniques best suited to the p53 cancer rescue mutant problem and <italic>in vivo</italic> results showing how well those techniques performed in experiments. The <xref ref-type="sec" rid="s4">Discussion</xref> section recites medical significance, sketches possible computational extensions of the MIP method, and concludes that a computational classifier and modeled structure-based features can guide function-based experimental discovery.</p></sec></sec><sec sec-type="methods" id="s2"><title>Methods</title><p>Active learning refers to a body of iterative machine learning techniques designed to train an accurate classifier using the minimum number of expensive examples <xref ref-type="bibr" rid="pcbi.1000498-Cohn1">&#x0005b;29&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pcbi.1000498-Roy1">&#x0005b;32&#x0005d;</xref>. The Most Informative Positive (MIP) method, introduced here, preferentially selects examples (i.e., p53 mutants) predicted to be both informative and Positive. The MIP computational method can be used to modify any active learning method that does not consider predicted class as a criterion for choosing which expensive examples to learn. Here, MIP modified the active learning algorithms described in <xref ref-type="bibr" rid="pcbi.1000498-Danziger2">&#x0005b;4&#x0005d;</xref> and was used to select regions in the p53 tumor suppressor protein.</p><p>This section contains:</p><list list-type="order"><list-item><p>An introduction to structure-based features and active learning.</p></list-item><list-item><p>A description of the MIP active learning method.</p></list-item><list-item><p>Metrics for evaluating how quickly an active learning algorithm uncovers Positive mutants.</p></list-item><list-item><p>The data sets used for <italic>in silico</italic> evaluation.</p></list-item><list-item><p>The general Regional Selection algorithm.</p></list-item><list-item><p>Regional Selection as implemented for the p53 cancer rescue problem.</p></list-item><list-item><p>A brief overview of the biological techniques used to test the mutant regions.</p></list-item></list><sec id="s2a"><title>Foundations: Structure-Based Features and Active Learning</title><p>The techniques presented in this paper build on previous research using machine learning techniques to find p53 cancer rescue mutants <xref ref-type="bibr" rid="pcbi.1000498-Danziger1">&#x0005b;3&#x0005d;</xref>,<xref ref-type="bibr" rid="pcbi.1000498-Danziger2">&#x0005b;4&#x0005d;</xref>. This section contains a brief overview of the foundational structure-based features and active learning techniques.</p><p>Structure-based features <xref ref-type="bibr" rid="pcbi.1000498-Danziger1">&#x0005b;3&#x0005d;</xref>,<xref ref-type="bibr" rid="pcbi.1000498-Danziger2">&#x0005b;4&#x0005d;</xref> for each mutant considered were extracted from atomic-level homology models. Modeled mutant proteins were produced <italic>in silico</italic> using the B chain of the wildtype p53 core domain crystal structure (PDB ID: 1TSR) <xref ref-type="bibr" rid="pcbi.1000498-Cho1">&#x0005b;33&#x0005d;</xref>. Amino acids were substituted and model energies were minimized using the Amber&#x02122; molecular modeling software <xref ref-type="bibr" rid="pcbi.1000498-Case1">&#x0005b;34&#x0005d;</xref>. Features <xref ref-type="bibr" rid="pcbi.1000498-Danziger1">&#x0005b;3&#x0005d;</xref> were extracted from the minimized mutant model using 1D sequence and amino acid substitution information, 2D surface cartographical and electrostatic models, 3D steric analysis, and &#x0201c;4D&#x0201d; thermal stability predictions. Those features on the surface of the p53 core domain outside known binding sites <xref ref-type="bibr" rid="pcbi.1000498-Friedler1">&#x0005b;35&#x0005d;</xref> were compressed, resulting in 5,867 features per mutant. Conditional Mutual Information Maximization <xref ref-type="bibr" rid="pcbi.1000498-Francois1">&#x0005b;36&#x0005d;</xref> selected various subsets of these features. It was found that 550 selected features resulted in the highest classifier accuracy <xref ref-type="bibr" rid="pcbi.1000498-Danziger2">&#x0005b;4&#x0005d;</xref>.</p><p>Seven previously studied <xref ref-type="bibr" rid="pcbi.1000498-Danziger2">&#x0005b;4&#x0005d;</xref> active learning algorithms were used here. Two of these methods are standard active learning techniques, taken from the literature, that work by separating the data into two classes with an n-dimensional hyper-plane. Minimum Marginal Hyperplane <xref ref-type="bibr" rid="pcbi.1000498-Hearst1">&#x0005b;37&#x0005d;</xref> selects examples based on the margin, i.e., the &#x0201c;distance&#x0201d; from the hyper-plane. Maximum Entropy <xref ref-type="bibr" rid="pcbi.1000498-Feng1">&#x0005b;38&#x0005d;</xref> selects examples based on a class probability calculated from the margin and is related to the information theory concept of entropy. Two methods, Maximum Marginal Hyperplane and Minimum Entropy, are negative controls expected to perform badly. They were created by choosing the least informative example in the previous two methods. The other three methods were created specifically for this p53 cancer rescue research project <xref ref-type="bibr" rid="pcbi.1000498-Danziger2">&#x0005b;4&#x0005d;</xref> and are based on the anticipated change in classifier accuracy or correlation coefficient if a given example is chosen and labeled. These include Additive/Maximum Curiosity <xref ref-type="bibr" rid="pcbi.1000498-Danziger2">&#x0005b;4&#x0005d;</xref>, which uses a cross-validated correlation coefficient to estimate classifier accuracy, and Additive Bayesian Surprise, which is based on the Kullback-Leibler (KL) divergence <xref ref-type="bibr" rid="pcbi.1000498-Itti1">&#x0005b;39&#x0005d;</xref>.</p></sec><sec id="s2b"><title>MIP Methodology</title><p>MIP optimizes the mutants chosen so that they are most likely to both improve the classifier and rapidly uncover Positive examples. To understand why this is important, suppose that Positive examples are sparse, as here, and one has only sufficient resources to assay 100 new examples. MIP active learning seeks to maximize the number of novel Positive examples discovered during those 100 assays, and at the same time quickly improve classifier accuracy. Traditional active learning also seeks to find an accurate classifier quickly, but may discover only very few novel Positives while so doing.</p><p>MIP active learning chooses <inline-formula><inline-graphic xlink:href="pcbi.1000498.e030.jpg" mimetype="image"/></inline-formula> by first considering only those unlabeled examples predicted to be Positive (i.e., <inline-formula><inline-graphic xlink:href="pcbi.1000498.e031.jpg" mimetype="image"/></inline-formula>&#x0200a;&#x0003d;&#x0200a;Positive). Those predicted to be Positive and having the highest score, <inline-formula><inline-graphic xlink:href="pcbi.1000498.e032.jpg" mimetype="image"/></inline-formula>, are chosen for <inline-formula><inline-graphic xlink:href="pcbi.1000498.e033.jpg" mimetype="image"/></inline-formula>. Only if too few examples in <inline-formula><inline-graphic xlink:href="pcbi.1000498.e034.jpg" mimetype="image"/></inline-formula> were predicted to be Positive would a Negative informative example be chosen for <inline-formula><inline-graphic xlink:href="pcbi.1000498.e035.jpg" mimetype="image"/></inline-formula>.</p><p>Active learning algorithms may become MIP algorithms by preferentially labeling those informative examples that are also predicted to be Positive. There are many ways to apply MIP to a specific active learning algorithm. Here we give a simple example, which shows a general approach and applies to nearly all active learning algorithms. Recall that <inline-formula><inline-graphic xlink:href="pcbi.1000498.e036.jpg" mimetype="image"/></inline-formula> ranks unlabeled examples, and high-ranking examples are chosen to be labeled at the next iteration. To convert a traditional active learning algorithm to a MIP active learning algorithm, it is sufficient to weight the scoring function so that examples predicted to be Positive have a higher score than those predicted to be Negative:<disp-formula><graphic xlink:href="pcbi.1000498.e037"/><label>(1)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="pcbi.1000498.e038.jpg" mimetype="image"/></inline-formula> is a constant with <inline-formula><inline-graphic xlink:href="pcbi.1000498.e039.jpg" mimetype="image"/></inline-formula> if <inline-formula><inline-graphic xlink:href="pcbi.1000498.e040.jpg" mimetype="image"/></inline-formula>&#x0200a;&#x0003d;&#x0200a;Positive, and <inline-formula><inline-graphic xlink:href="pcbi.1000498.e041.jpg" mimetype="image"/></inline-formula> if <inline-formula><inline-graphic xlink:href="pcbi.1000498.e042.jpg" mimetype="image"/></inline-formula>&#x0200a;&#x0003d;&#x0200a;Negative.</p></sec><sec id="s2c"><title>Metrics: Halfway Point, Accuracy, Correlation Coefficient</title><p>For this paper and much biological research, the goal of iterative exploration is to uncover as many informative Positive examples as quickly as possible, i.e., with the fewest biological experiments. We require metrics to measure success at this task.</p><p>The Halfway Point metric measures the fraction of iterations necessary before half of all Positive examples in an unlabeled data set are uncovered. Several additional metrics were explored to measure how quickly Positive examples were found, including enrichment factor and positive area, but only Halfway Point is presented here for illustrative clarity because it is simple to explain and it provides similar results to the other metrics.</p><p>Formally, Halfway Point&#x0200a;&#x0003d;&#x0200a;<inline-formula><inline-graphic xlink:href="pcbi.1000498.e043.jpg" mimetype="image"/></inline-formula>, where <inline-formula><inline-graphic xlink:href="pcbi.1000498.e044.jpg" mimetype="image"/></inline-formula>is the smallest number of iterations such that <inline-formula><inline-graphic xlink:href="pcbi.1000498.e045.jpg" mimetype="image"/></inline-formula>contains half of all Positive mutants in <inline-formula><inline-graphic xlink:href="pcbi.1000498.e046.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pcbi.1000498.e047.jpg" mimetype="image"/></inline-formula>is the number of mutants labeled at each iteration.</p><p>Since MIP optimizes a classifier to preferentially choose Positive mutants for <inline-formula><inline-graphic xlink:href="pcbi.1000498.e048.jpg" mimetype="image"/></inline-formula>, it is reasonable to wonder if there may be a corresponding loss of classifier accuracy. One way to estimate classifier accuracy for an active learning algorithm is to use the average 10-fold cross-validated accuracy and correlation coefficient of the training set <inline-formula><inline-graphic xlink:href="pcbi.1000498.e049.jpg" mimetype="image"/></inline-formula> across all iterations of one or more of the Data Partitions described below. Accuracy is the fraction of correct predictions. The correlation coefficient is a standard of the machine learning community <xref ref-type="bibr" rid="pcbi.1000498-Baldi1">&#x0005b;40&#x0005d;</xref>, and a better measure than accuracy when the data set contains unbalanced numbers of Positive and Negative examples. This is the usual case for biological data sets such as the p53 cancer rescue mutant data set, where the ratio of Negative to Positive mutants is about 4&#x02236;1.</p><p>Several other metrics for accuracy were explored, including forward prediction accuracy, 3-point accuracy, and a more complicated cross-validation strategy, OECV <xref ref-type="bibr" rid="pcbi.1000498-Danziger2">&#x0005b;4&#x0005d;</xref>. Average 10-fold cross-validated accuracy and correlation coefficient were chosen for illustrative clarity here because they are simple to explain and give similar results to the other metrics.</p></sec><sec id="s2d"><title>Evaluation <italic>In Silico</italic></title><p>To evaluate the MIP methodology <italic>in silico</italic>, MIP and non-MIP versions of seven active learning methods plus a random control were compared using the cross-validated metrics described above. Three previously studied partitions of the data set <xref ref-type="bibr" rid="pcbi.1000498-Danziger2">&#x0005b;4&#x0005d;</xref> were used to compare to previous research. These partitions test three common starting conditions for active learning:</p><list list-type="order"><list-item><p>Data Partition 1: Few mutants in <inline-formula><inline-graphic xlink:href="pcbi.1000498.e050.jpg" mimetype="image"/></inline-formula>and many in <inline-formula><inline-graphic xlink:href="pcbi.1000498.e051.jpg" mimetype="image"/></inline-formula>, i.e., <inline-formula><inline-graphic xlink:href="pcbi.1000498.e052.jpg" mimetype="image"/></inline-formula>&#x0200a;&#x0003d;&#x0200a;25 and <inline-formula><inline-graphic xlink:href="pcbi.1000498.e053.jpg" mimetype="image"/></inline-formula>&#x0200a;&#x0003d;&#x0200a;236.</p></list-item><list-item><p>Data Partition 2: Similar numbers of mutants in <inline-formula><inline-graphic xlink:href="pcbi.1000498.e054.jpg" mimetype="image"/></inline-formula>and <inline-formula><inline-graphic xlink:href="pcbi.1000498.e055.jpg" mimetype="image"/></inline-formula>, i.e., <inline-formula><inline-graphic xlink:href="pcbi.1000498.e056.jpg" mimetype="image"/></inline-formula>&#x0200a;&#x0003d;&#x0200a;123 and <inline-formula><inline-graphic xlink:href="pcbi.1000498.e057.jpg" mimetype="image"/></inline-formula>&#x0200a;&#x0003d;&#x0200a;138.</p></list-item><list-item><p>Data Partition 3: Many mutants in <inline-formula><inline-graphic xlink:href="pcbi.1000498.e058.jpg" mimetype="image"/></inline-formula>and few in <inline-formula><inline-graphic xlink:href="pcbi.1000498.e059.jpg" mimetype="image"/></inline-formula>, i.e., <inline-formula><inline-graphic xlink:href="pcbi.1000498.e060.jpg" mimetype="image"/></inline-formula>&#x0200a;&#x0003d;&#x0200a;204 and <inline-formula><inline-graphic xlink:href="pcbi.1000498.e061.jpg" mimetype="image"/></inline-formula>&#x0200a;&#x0003d;&#x0200a;57.</p></list-item></list><p>The data set had about 20&#x00025; Positive and 80&#x00025; Negative mutants.</p></sec><sec id="s2e"><title>Regional Selection</title><p>Active learning and MIP as discussed so far apply to individual mutants. Limitations of this approach include loss of classifier accuracy when applied to new mutants from unfamiliar regions, leading to many experiments that yielded few Positive examples <xref ref-type="bibr" rid="pcbi.1000498-Danziger2">&#x0005b;4&#x0005d;</xref>. We generalized MIP active learning to apply to single amino acid changes in contiguous gene regions. This generalization supported several desirable outcomes. It allowed MIP active learning to exploit high throughput saturation mutagenesis techniques. The resulting training set enrichment should allow more accurate prediction of new Positive mutants, especially those requiring multiple amino acid changes. Regions enriched for rescue mutants may indicate promising candidate drug target sites.</p><p>Formally, let <inline-formula><inline-graphic xlink:href="pcbi.1000498.e062.jpg" mimetype="image"/></inline-formula> be the set of all mutants containing a cancer mutation plus a single putative rescue at amino acid location <inline-formula><inline-graphic xlink:href="pcbi.1000498.e063.jpg" mimetype="image"/></inline-formula>, excluding mutants that exist in the initial training set <inline-formula><inline-graphic xlink:href="pcbi.1000498.e064.jpg" mimetype="image"/></inline-formula>. Let<disp-formula><graphic xlink:href="pcbi.1000498.e065"/><label>(2)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="pcbi.1000498.e066.jpg" mimetype="image"/></inline-formula> is the subset of <inline-formula><inline-graphic xlink:href="pcbi.1000498.e067.jpg" mimetype="image"/></inline-formula>for which <inline-formula><inline-graphic xlink:href="pcbi.1000498.e068.jpg" mimetype="image"/></inline-formula>&#x0200a;&#x0003d;&#x0200a;Positive. Positive regions were ranked by summing <inline-formula><inline-graphic xlink:href="pcbi.1000498.e069.jpg" mimetype="image"/></inline-formula> across each region. The Positive Region used below was chosen to be the 10 sequential amino acid long window with the highest average <inline-formula><inline-graphic xlink:href="pcbi.1000498.e070.jpg" mimetype="image"/></inline-formula> across that window.</p><p>Similarly, let<disp-formula><graphic xlink:href="pcbi.1000498.e071"/><label>(3)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="pcbi.1000498.e072.jpg" mimetype="image"/></inline-formula>is the subset of <inline-formula><inline-graphic xlink:href="pcbi.1000498.e073.jpg" mimetype="image"/></inline-formula>for which <inline-formula><inline-graphic xlink:href="pcbi.1000498.e074.jpg" mimetype="image"/></inline-formula>&#x0200a;&#x0003d;&#x0200a;Negative. The Negative Region was chosen to be the 10 sequential amino acid long window with the highest average <inline-formula><inline-graphic xlink:href="pcbi.1000498.e075.jpg" mimetype="image"/></inline-formula> across that window.</p><p>A similar non-MIP control region was constructed to be informative to the classifier regardless of whether mutants were predicted to be Positive or Negative. Let<disp-formula><graphic xlink:href="pcbi.1000498.e076"/><label>(4)</label></disp-formula></p><p>The non-MIP Region was chosen to be the 10 sequential amino acid long window with the highest average <inline-formula><inline-graphic xlink:href="pcbi.1000498.e077.jpg" mimetype="image"/></inline-formula> across that window.</p></sec><sec id="s2f"><title>Regional Selection Implementation</title><p>To detect p53 cancer rescue regions, the task is to identify areas of the p53 core domain that are likely to have many Positive cancer rescue mutants. We considered ten p53 cancer mutants that are commonly found in human cancer <xref ref-type="bibr" rid="pcbi.1000498-Petitjean1">&#x0005b;12&#x0005d;</xref> and can be constructed so that they differ by two or more nucleic acid changes from the wild-type. <inline-formula><inline-graphic xlink:href="pcbi.1000498.e078.jpg" mimetype="image"/></inline-formula> consisted of these 10 common p53 cancer mutants paired with all possible single amino acid changes at each location in the core domain. All predictions and curiosity calculations were made with a training set, <inline-formula><inline-graphic xlink:href="pcbi.1000498.e079.jpg" mimetype="image"/></inline-formula>, of 463 mutants (91 Positive and 372 Negative). These 463 mutants contained the 261 mutants used for the Data Partitions plus 202 created during other experiments using variants of the yeast assay described below <xref ref-type="bibr" rid="pcbi.1000498-Danziger1">&#x0005b;3&#x0005d;</xref>,<xref ref-type="bibr" rid="pcbi.1000498-Danziger2">&#x0005b;4&#x0005d;</xref>,<xref ref-type="bibr" rid="pcbi.1000498-Baroni1">&#x0005b;13&#x0005d;</xref>,<xref ref-type="bibr" rid="pcbi.1000498-Brachmann1">&#x0005b;14&#x0005d;</xref>.</p><p>The MIP Additive Curiosity <xref ref-type="bibr" rid="pcbi.1000498-Danziger2">&#x0005b;4&#x0005d;</xref> algorithm was used to choose the regions because it performed best in <italic>in silico</italic> trials (see <xref ref-type="sec" rid="s4">Results</xref>). It was adapted to select three 10-amino acid long regions in the p53 core domain: a Positive region, a Negative region, and a non-MIP control region. A Weka Support Vector Machine, SMO, <xref ref-type="bibr" rid="pcbi.1000498-Witten1">&#x0005b;41&#x0005d;</xref>, was used to predict the activity, <inline-formula><inline-graphic xlink:href="pcbi.1000498.e080.jpg" mimetype="image"/></inline-formula>, for each mutant. The score for each mutant was calculated using MIP Additive Curiosity. These values were averaged over every possible 10-amino acid window. The classifier considered the resulting 34,776 putative cancer rescue mutants and selected &#x0223c;3,980 mutants in three regions. These regions were selected for the following criteria as described above:</p><list list-type="order"><list-item><p>Positive Region: predicted to be informative and contain novel Positive mutants.</p></list-item><list-item><p>Negative Region: a control predicted to be informative and contain few Positive mutants.</p></list-item><list-item><p>non-MIP Region: a control predicted to be informative regardless of mutant activity.</p><p>As another control, these regions were compared to:</p></list-item><list-item><p>Expert Region: a control selected for biological considerations by an expert p53 cancer rescue biologist and hypothesized to contain Positive cancer rescue mutants.</p></list-item></list><p>The Expert Region, spanning residues 114&#x02013;123, was considered a potential cancer rescue region because several Positive mutations with multiple amino acid changes occurred there spontaneously in previous cancer rescue mutant screens. Therefore, this region was considered likely to have cancer rescue mutants with single amino acid changes (<xref ref-type="bibr" rid="pcbi.1000498-Baroni1">&#x0005b;13&#x0005d;</xref>; Brachmann, R. K., personal communication).</p><p>No single amino acid change cancer rescue mutations had been found previously in any of the Positive, Negative, non-MIP, or Expert regions.</p></sec><sec id="s2g"><title>Regional Saturation Mutagenesis and Yeast Assay</title><p>All mutants produced in this study were initially created with a novel regional saturation mutagenesis method based on the Quick Change site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA), (manuscript in preparation). Briefly, a set of overlapping degenerate oligonucleotides was designed such that each primer contained exactly one random codon. A standard site-directed mutagenesis reaction was performed with a mixture of oligonucleotides that collectively represented each possible codon change in the target region (30 base pairs). The overlapping primer design prevented multiple mutations in the same mutagenesis product. The generated mutants were analyzed for p53 activity using a yeast-based p53 activity assay <xref ref-type="bibr" rid="pcbi.1000498-Baroni1">&#x0005b;13&#x0005d;</xref>.</p><p>Briefly, yeast cells were engineered to depend on active p53 for expression of the <italic>URA3</italic> gene. The <italic>URA3</italic> gene product is required for the synthesis of uracil. When cells are grown in medium lacking uracil, cell growth is proportional to p53 activity (<italic>URA3</italic> expression). The products of the saturation mutagenesis for all ten p53 cancer mutants in all tested regions were first selected for their ability to grow in the absence of uracil, indicating re-activated p53. All putative positive mutants were analyzed by DNA sequencing to determine the nature of the rescue mutation. Mutations were then recreated by site-directed mutagenesis, confirmed by resequencing, and retested.</p><p>As shown in <xref ref-type="fig" rid="pcbi-1000498-g001">Figure 1</xref>, mutants were designated as strong Positive mutants if the yeast cell growth was very robust. Mutants contained in yeasts that showed minimal growth were designated as weak Positive mutants. Strong and weak Positive mutants were collectively designated Positive. Those that did not grow were designated Negative. p53 mutants are described as &#x0003c;Cancer Mutation&#x0003e;_&#x0003c;putative rescue mutation&#x0003e;. For example, P152L_q100i identifies a cancer mutation with leucine replacing proline at amino acid 152 and a putative rescue mutation with isoleucine replacing glutamine at amino acid 100.</p><fig id="pcbi-1000498-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000498.g001</object-id><label>Figure 1</label><caption><title>Growth results at different yeast concentrations.</title><p>Wild-type refers to yeasts containing the wild-type p53 strain. Mutants annotated with (S) are strong Positive cancer rescue mutants, (W) are weak Positive cancer rescue mutants, and (N) are Negative mutants. Different numbers of yeast cells expressing wild-type or mutant p53 as indicated were spotted on growth media. The numbers of cells spotted (from left to right) was 10,000, 2,000 and 400 cells. Cells were then cultured at 37&#x000b0;C for 2 days and cell growth was assessed by the observable increase in cells, which is proportional to the starting cell number. Rescue mutants were designated as &#x0201c;strong&#x0201d; if they showed better growth at the 2,000 cells per spot position than the cancer mutant at 10,000 cells per spot. Rescue mutants were considered &#x0201c;weak&#x0201d; when growth advantage was only obvious when the 10,000 cells per spot were compared between rescue mutant and cancer mutant.</p></caption><graphic xlink:href="pcbi.1000498.g001"/></fig></sec></sec><sec id="s3"><title>Results</title><p>Most Informative Positive (MIP) active learning was designed to find Positive examples, here p53 cancer rescue mutants, as quickly as possible. Fourteen active learning methods (seven implemented as MIP algorithms) and one random control were tested. The MIP method Additive Curiosity performed best <italic>in silico</italic>, so was used to select the Positive, Negative, and non-MIP regions. These regions were assayed for novel p53 cancer rescue mutants.</p><p>This section contains:</p><list list-type="order"><list-item><p>The <italic>in silico</italic> performance comparison of MIP and non-MIP active learning algorithms.</p></list-item><list-item><p>The regions selected by the regional selection algorithms.</p></list-item><list-item><p>Novel rescue mutants discovered in the Positive, Negative, and non-MIP regions.</p></list-item><list-item><p>Other predicted p53 regions.</p></list-item><list-item><p>3D Visualizations of the putative rescue regions and significant mutants.</p></list-item></list><sec id="s3a"><title>Comparison of MIP and non-MIP Active Learning Methods</title><p>For the purposes of this study, the best active learning method was the method with the lowest Halfway Point, i.e., the method that discovered half of the Positive mutants in the test set using the smallest fraction of possible iterations. From <xref ref-type="table" rid="pcbi-1000498-t001">Table 1</xref>, the best MIP method reached the Halfway Point in 33&#x00025; fewer iterations, and the average MIP algorithm needed 28&#x00025; fewer iterations, than their non-MIP counterparts (p&#x0003c;0.006). Even the MIP versions of the negative control methods, Maximum Marginal Hyperplane and Minimum Entropy, performed better than any of the non-MIP methods.</p><table-wrap id="pcbi-1000498-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000498.t001</object-id><label>Table 1</label><caption><title>Active learning halfway points.</title></caption><alternatives><graphic id="pcbi-1000498-t001-1" xlink:href="pcbi.1000498.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Active Learning Type</td><td align="left" rowspan="1" colspan="1">non-MIP</td><td align="left" rowspan="1" colspan="1">MIP</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Additive Curiosity</bold></td><td align="left" rowspan="1" colspan="1">0.472</td><td align="left" rowspan="1" colspan="1"><bold>0.317</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Maximum Curiosity</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.406</bold></td><td align="left" rowspan="1" colspan="1">0.341</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Minimum Marginal Hyperplane</bold></td><td align="left" rowspan="1" colspan="1">0.423</td><td align="left" rowspan="1" colspan="1">0.356</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Additive Bayesian Surprise</bold></td><td align="left" rowspan="1" colspan="1">0.463</td><td align="left" rowspan="1" colspan="1">0.365</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Maximum Entropy</bold></td><td align="left" rowspan="1" colspan="1">0.461</td><td align="left" rowspan="1" colspan="1">0.388</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Minimum Entropy</bold></td><td align="left" rowspan="1" colspan="1">0.666</td><td align="left" rowspan="1" colspan="1">0.381</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Maximum Marginal Hyperplane</bold></td><td align="left" rowspan="1" colspan="1">0.639</td><td align="left" rowspan="1" colspan="1">0.403</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Random (100 Trials)</bold></td><td align="center" rowspan="1" colspan="1">0.502</td><td align="left" rowspan="1" colspan="1">&#x0002b;/&#x02212;0.084</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><p>The Halfway Points are averaged across the three data sets discussed in the <xref ref-type="sec" rid="s2">Methods</xref> section. Applying a paired Student's t-test to these seven active learning methods reveals a two-tailed p-value&#x0200a;&#x0003d;&#x0200a;0.011.</p></fn></table-wrap-foot></table-wrap><p>A graph showing the Halfway Point for select active learning types with Data Partition 1, <inline-formula><inline-graphic xlink:href="pcbi.1000498.e081.jpg" mimetype="image"/></inline-formula>&#x0200a;&#x0003d;&#x0200a;25 and <inline-formula><inline-graphic xlink:href="pcbi.1000498.e082.jpg" mimetype="image"/></inline-formula>&#x0200a;&#x0003d;&#x0200a;236, is presented in <xref ref-type="fig" rid="pcbi-1000498-g002">Figure 2</xref>.</p><fig id="pcbi-1000498-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000498.g002</object-id><label>Figure 2</label><caption><title>MIP versus non-MIP halfway points.</title><p>Shown are the fraction of Positive mutants uncovered by MIP Maximum Curiosity and Additive Curiosity compared with their non-MIP counterparts. The intersections with the dotted horizontal line correspond to the Halfway Point.</p></caption><graphic xlink:href="pcbi.1000498.g002"/></fig><p>Applying the MIP methodology improves how quickly a given active learning algorithm uncovers the Positive mutants, but what effect does it have on overall classifier accuracy? The 10-fold cross-validated results, presented in <xref ref-type="table" rid="pcbi-1000498-t002">Table 2</xref> and <xref ref-type="table" rid="pcbi-1000498-t003">Table 3</xref>, show that MIP reduced the cross-validated accuracy by on average 1.1&#x00025; (statistically significant, p-Value&#x0200a;&#x0003d;&#x0200a;0.012) and the correlation coefficient by on average 0.001 (not significant, p-Value&#x0200a;&#x0003d;&#x0200a;0.755).</p><table-wrap id="pcbi-1000498-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000498.t002</object-id><label>Table 2</label><caption><title>10-fold cross-validated accuracy.</title></caption><alternatives><graphic id="pcbi-1000498-t002-2" xlink:href="pcbi.1000498.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Active Learning Type</td><td align="left" rowspan="1" colspan="1">non-MIP</td><td align="left" rowspan="1" colspan="1">MIP</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Additive Curiosity</bold></td><td align="left" rowspan="1" colspan="1">73.4&#x00025;</td><td align="left" rowspan="1" colspan="1"><bold>73.5&#x00025;</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Maximum Curiosity</bold></td><td align="left" rowspan="1" colspan="1">72.9&#x00025;</td><td align="left" rowspan="1" colspan="1">72.7&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Minimum Marginal Hyperplane</bold></td><td align="left" rowspan="1" colspan="1">73.4&#x00025;</td><td align="left" rowspan="1" colspan="1">72.1&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Additive Bayesian Surprise</bold></td><td align="left" rowspan="1" colspan="1">74.7&#x00025;</td><td align="left" rowspan="1" colspan="1">72.5&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Maximum Entropy</bold></td><td align="left" rowspan="1" colspan="1">73.3&#x00025;</td><td align="left" rowspan="1" colspan="1">72.1&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Minimum Entropy</bold></td><td align="left" rowspan="1" colspan="1">73.4&#x00025;</td><td align="left" rowspan="1" colspan="1">72.3&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Maximum Marginal Hyperplane</bold></td><td align="left" rowspan="1" colspan="1"><bold>74.9&#x00025;</bold></td><td align="left" rowspan="1" colspan="1">73.1&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Average of seven methods above</bold></td><td align="left" rowspan="1" colspan="1">73.7&#x00025;</td><td align="left" rowspan="1" colspan="1">72.6&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Random (100 Trials)</bold></td><td align="center" rowspan="1" colspan="1">72.4&#x00025;</td><td align="left" rowspan="1" colspan="1">&#x0002b;/&#x02212;4.36</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><p>The average 10-fold cross-validated accuracy for all training sets across the three Data Partitions discussed in the <xref ref-type="sec" rid="s2">Methods</xref> section. Applying a paired Student's t-test to these seven active learning methods reveals a two-tailed p-value&#x0200a;&#x0003d;&#x0200a;0.012.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pcbi-1000498-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000498.t003</object-id><label>Table 3</label><caption><title>10-fold cross-validated correlation coefficient.</title></caption><alternatives><graphic id="pcbi-1000498-t003-3" xlink:href="pcbi.1000498.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Active Learning Type</td><td align="left" rowspan="1" colspan="1">non-MIP</td><td align="left" rowspan="1" colspan="1">MIP</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Additive Curiosity</bold></td><td align="left" rowspan="1" colspan="1">.402</td><td align="left" rowspan="1" colspan="1"><bold>.423</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Maximum Curiosity</bold></td><td align="left" rowspan="1" colspan="1">.390</td><td align="left" rowspan="1" colspan="1">.400</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Minimum Marginal Hyperplane</bold></td><td align="left" rowspan="1" colspan="1">.404</td><td align="left" rowspan="1" colspan="1">.392</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Additive Bayesian Surprise</bold></td><td align="left" rowspan="1" colspan="1"><bold>.428</bold></td><td align="left" rowspan="1" colspan="1">.404</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Maximum Entropy</bold></td><td align="left" rowspan="1" colspan="1">.393</td><td align="left" rowspan="1" colspan="1">.386</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Minimum Entropy</bold></td><td align="left" rowspan="1" colspan="1">.370</td><td align="left" rowspan="1" colspan="1">.381</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Maximum Marginal Hyperplane</bold></td><td align="left" rowspan="1" colspan="1">.409</td><td align="left" rowspan="1" colspan="1">.396</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Average of seven methods above</bold></td><td align="left" rowspan="1" colspan="1">.399</td><td align="left" rowspan="1" colspan="1">.398</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Random (100 Trials)</bold></td><td align="left" rowspan="1" colspan="1">.304</td><td align="left" rowspan="1" colspan="1">&#x0002b;/&#x02212;.131</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><p>The average 10-fold cross-validated correlation coefficient for all training sets across the three Data Partitions discussed in the <xref ref-type="sec" rid="s2">Methods</xref> section. Applying a paired Student's t-test to these seven active learning methods reveals a two-tailed p-value&#x0200a;&#x0003d;&#x0200a;0.755.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Positive, Negative, Non-MIP, and Expert Regions</title><p>The MIP Additive Curiosity algorithm performed best in <xref ref-type="table" rid="pcbi-1000498-t001">Tables 1</xref>, <xref ref-type="table" rid="pcbi-1000498-t002">2</xref>, and <xref ref-type="table" rid="pcbi-1000498-t003">3</xref>, and so was used to select three 10 amino acid long regions as the Positive, Negative, and non-MIP Regions. The Positive Region from residues 96&#x02013;105 had the highest average <inline-formula><inline-graphic xlink:href="pcbi.1000498.e083.jpg" mimetype="image"/></inline-formula> score (.938) and contained 351 mutants predicted to be Positive out of 1900 total. The Negative Region from residues 223&#x02013;232 had the highest average <inline-formula><inline-graphic xlink:href="pcbi.1000498.e084.jpg" mimetype="image"/></inline-formula> score (.937) and contained 33 mutants predicted to be Positive. The non-MIP Region from residues 222&#x02013;231 had the highest <inline-formula><inline-graphic xlink:href="pcbi.1000498.e085.jpg" mimetype="image"/></inline-formula> score (.938) and contained 53 mutants predicted to be Positive. For comparison, the Expert Region from residues 114&#x02013;123 had a <inline-formula><inline-graphic xlink:href="pcbi.1000498.e086.jpg" mimetype="image"/></inline-formula> score of (.462) and contained 34 mutants predicted to be Positive. See <xref ref-type="fig" rid="pcbi-1000498-g003">Figure 3</xref> for the scores across possible Positive and Negative Regions and <xref ref-type="fig" rid="pcbi-1000498-g004">Figure 4</xref> for a graph illustrating those regions within the p53 core domain.</p><fig id="pcbi-1000498-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000498.g003</object-id><label>Figure 3</label><caption><title>Scores for Positive and Negative Regions using Additive Curiosity.</title><p>The score at each residue is the average Additive Curiosity score for the preceding ten residues. For example, the Positive Score at residue 105 scores the region from 96&#x02013;105 to test if it is the best Positive Region. The non-MIP Scores are omitted because they are nearly indistinguishable from the Negative Scores.</p></caption><graphic xlink:href="pcbi.1000498.g003"/></fig><fig id="pcbi-1000498-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000498.g004</object-id><label>Figure 4</label><caption><title>Regional saturation mutagenesis scores and selections.</title><p>Count indicates the number of mutants predicted to be Positive at each residue in the p53 core domain and is represented as black dots corresponding to the leftmost y-axis. Average Curiosity Score is the average Additive Curiosity score for the mutants predicted to be Positive at each residue and is represented as solid purple diamonds connected with lines and corresponding to the rightmost y-axis. The solid green circles indicate contiguous regions of 10 or more residues that have high Curiosity and are predicted to be Positive. The solid red squares indicate the contiguous regions of 10 or more residues that have high Curiosity and are predicted to be Negative. The purple diamonds indicate contiguous regions that an expert might expect to contain rescue mutants based on previous experiments. The light blue &#x0002b;s with the lines descending to the x-axis indicate the region explored in Baroni, et al., (2004), though this region is not treated specially, nor is even known, by the classifier. The Positive, non-MIP, Negative, and Expert regions ultimately selected are presented above the plot and labeled with P, n, N, and E respectively. No single amino acid rescue mutations had been found previously in any of the Positive, non-MIP, Negative, or Expert regions.</p></caption><graphic xlink:href="pcbi.1000498.g004"/></fig><p>Regional Saturation Mutagenesis produced all possible single amino acid mutations in these regions combined with the 10 common cancer mutants tested. A biological selection was performed to identify all rescue mutants based on re-activation of p53 cancer mutants <italic>in vivo</italic>.</p><p>The summary of these results is recorded in <xref ref-type="table" rid="pcbi-1000498-t004">Table 4</xref>. The Positive Region contained 8 strong and 3 weak mutants, the Expert Regions contained 6 strong and 7 weak mutants, while the Negative and non-MIP regions each contained only 2 weak mutants.</p><table-wrap id="pcbi-1000498-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000498.t004</object-id><label>Table 4</label><caption><title>Novel Positive cancer rescue mutant counts &#x00026; statistics.</title></caption><alternatives><graphic id="pcbi-1000498-t004-4" xlink:href="pcbi.1000498.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">non-MIP</td><td align="left" rowspan="1" colspan="1">Expert</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(96&#x02013;105)</td><td align="left" rowspan="1" colspan="1">(223&#x02013;232)</td><td align="left" rowspan="1" colspan="1">(222&#x02013;231)</td><td align="left" rowspan="1" colspan="1">(114&#x02013;123)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold># Strong</bold></td><td align="left" rowspan="1" colspan="1"><bold>8</bold></td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">p-value</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0.008</td><td align="left" rowspan="1" colspan="1">0.008</td><td align="left" rowspan="1" colspan="1">0.791</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold># Weak</bold></td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1"><bold>7</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">p-value</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">1.000</td><td align="left" rowspan="1" colspan="1">1.000</td><td align="left" rowspan="1" colspan="1">0.344</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold># Total</bold></td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1"><bold>13</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">p-value</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0.022</td><td align="left" rowspan="1" colspan="1">0.022</td><td align="left" rowspan="1" colspan="1">0.839</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt104"><p>The range of numbers listed below the region names are the amino acid locations covered by that region. All p-values are two-tailed p-values; the corresponding one-tailed values are half what is listed.</p></fn></table-wrap-foot></table-wrap><p><xref ref-type="table" rid="pcbi-1000498-t004">Table 4</xref> also shows the p-values associated with the null hypothesis &#x0201c;Positive mutants are equally likely to be drawn from the Positive Region as the Negative, non-MIP, or Expert Region.&#x0201d; From this analysis we are at least 99.5&#x00025; confident (one-tail) that the Positive Region contains more strong cancer rescue mutants than the Negative or non-MIP Region. Similarly, we infer that there is no significant difference between the number of cancer rescue mutants in the Positive and Expert regions.</p></sec><sec id="s3c"><title>Novel p53 Cancer Rescue Mutants</title><p>The novel p53 cancer rescue mutants found in the Positive, Negative, and non-MIP regions are presented in <xref ref-type="table" rid="pcbi-1000498-t005">Table 5</xref> and summarized in <xref ref-type="table" rid="pcbi-1000498-t006">Table 6</xref>. Three different cancer mutants were rescued by these regions: P152L, R158L and G245S. R158L was rescued strongly by the Positive Region, and weakly by the Negative and non-MIP regions. G245S was rescued weakly by the Negative and non-MIP regions. P152L, a previously unrescued cancer mutant, was rescued only by the Positive Region, and rescued strongly.</p><table-wrap id="pcbi-1000498-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000498.t005</object-id><label>Table 5</label><caption><title>Novel Positive cancer rescue mutants by name.</title></caption><alternatives><graphic id="pcbi-1000498-t005-5" xlink:href="pcbi.1000498.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Positive Region</td><td align="left" rowspan="1" colspan="1">Negative/non-MIP Region</td><td align="left" rowspan="1" colspan="1">Artifactual Mutants</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">P152L_q100i</td><td align="left" rowspan="1" colspan="1"><italic>R158L_e224p (W)</italic></td><td align="left" rowspan="1" colspan="1">P152L_s106p</td></tr><tr><td align="left" rowspan="1" colspan="1">P152L_q100s</td><td align="left" rowspan="1" colspan="1"><italic>G245S_t231y (W)</italic></td><td align="left" rowspan="1" colspan="1">P152L_l137m</td></tr><tr><td align="left" rowspan="1" colspan="1">P152L_q100t</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">P152L_d207e</td></tr><tr><td align="left" rowspan="1" colspan="1">P152L_y103c</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">R158L_l201p</td></tr><tr><td align="left" rowspan="1" colspan="1">R158L_q100f</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">R158L_q100h_q104a</td></tr><tr><td align="left" rowspan="1" colspan="1">R158L_q100n</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">R158L_q100a_q104r</td></tr><tr><td align="left" rowspan="1" colspan="1">R158L_q100s</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">R158L_q100t</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>P152L_q100a (W)</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>P152L_k101e (W)</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>P152L_k101n (W)</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt105"><p>Mutants are named with the cancer mutation appearing first with capital letters followed by the putative cancer rescue mutation(s) appearing after the underscore. P152L means that the proline at the 152<sup>nd</sup> amino acid location in p53 is mutated into a leucine. The mutants appearing italicized with a (W), e.g., P152L_k101e, etc., are weak cancer rescue mutants. All others are strong cancer rescue mutants. Artifactual Mutants are cancer rescue mutants that contained more than one cancer rescue mutation or were not in any of the regions, due to background mutagenesis and limitations in early versions of the saturation mutagenesis technique.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pcbi-1000498-t006" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000498.t006</object-id><label>Table 6</label><caption><title>Novel Positive cancer rescue mutants by cancer mutation.</title></caption><alternatives><graphic id="pcbi-1000498-t006-6" xlink:href="pcbi.1000498.t006"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Cancer Mutation</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">Non-MIP</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>(96&#x02013;105)</italic></td><td align="left" rowspan="1" colspan="1"><italic>(223&#x02013;232)</italic></td><td align="left" rowspan="1" colspan="1"><italic>(222&#x02013;231)</italic></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">7: R249S</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">8: G245S</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">(1)</td><td align="left" rowspan="1" colspan="1">(1)</td></tr><tr><td align="left" rowspan="1" colspan="1">14: H179R&#x0002a;</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">16: R273L</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">22: R248L</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">23: R158L</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">(1)</td><td align="left" rowspan="1" colspan="1">(1)</td></tr><tr><td align="left" rowspan="1" colspan="1">26: R280T&#x0002a;</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">27: P151S&#x0002a;</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">32: P152L&#x0002a;</td><td align="left" rowspan="1" colspan="1">4&#x0002b;(3)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">34: P278L&#x0002a;</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Total</bold></td><td align="left" rowspan="1" colspan="1">8&#x0002b;(3)</td><td align="left" rowspan="1" colspan="1">0&#x0002b;(2)</td><td align="left" rowspan="1" colspan="1">0&#x0002b;(2)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt106"><p>The number listed before the cancer mutant is the frequency rank of that cancer mutant occurring in human cancer. e.g., R249S is the 7<sup>th</sup> most frequent single codon p53 mutation found in human cancer biopsies <xref ref-type="bibr" rid="pcbi.1000498-Petitjean1">&#x0005b;12&#x0005d;</xref>. Weak Positive cancer rescue mutant counts are in parentheses. Mutants marked with asterisks had never been rescued at the beginning of this study.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3d"><title>Other Predicted p53 Regions</title><p>In addition to Additive Curiosity, six other (non-Random) active learning methods were considered. <xref ref-type="table" rid="pcbi-1000498-t007">Table 7</xref> shows the Positive, Negative, and non-MIP regions selected by those other methods. The non-MIP region was similar to the Negative region due to the preponderance of predicted Negative mutants in the test set.</p><table-wrap id="pcbi-1000498-t007" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000498.t007</object-id><label>Table 7</label><caption><title>Region selection by active learning algorithms.</title></caption><alternatives><graphic id="pcbi-1000498-t007-7" xlink:href="pcbi.1000498.t007"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Active Learning Type</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">non-MIP</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Additive Curiosity</bold></td><td align="left" rowspan="1" colspan="1">96&#x02013;105</td><td align="left" rowspan="1" colspan="1">223&#x02013;232</td><td align="left" rowspan="1" colspan="1">222&#x02013;231</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Maximum Curiosity</bold></td><td align="left" rowspan="1" colspan="1">100&#x02013;109</td><td align="left" rowspan="1" colspan="1">222&#x02013;231</td><td align="left" rowspan="1" colspan="1">222&#x02013;231</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Minimum Marginal Hyperplane</bold></td><td align="left" rowspan="1" colspan="1">141&#x02013;150</td><td align="left" rowspan="1" colspan="1">108&#x02013;117</td><td align="left" rowspan="1" colspan="1">122&#x02013;131</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Additive Bayesian Surprise</bold></td><td align="left" rowspan="1" colspan="1">96&#x02013;105</td><td align="left" rowspan="1" colspan="1">222&#x02013;231</td><td align="left" rowspan="1" colspan="1">222&#x02013;231</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Maximum Entropy</bold></td><td align="left" rowspan="1" colspan="1">243&#x02013;252</td><td align="left" rowspan="1" colspan="1">206&#x02013;215</td><td align="left" rowspan="1" colspan="1">206&#x02013;215</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Minimum Entropy</bold></td><td align="left" rowspan="1" colspan="1">170&#x02013;179</td><td align="left" rowspan="1" colspan="1">140&#x02013;149</td><td align="left" rowspan="1" colspan="1">140&#x02013;149</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Maximum Marginal Hyperplane</bold></td><td align="left" rowspan="1" colspan="1">210&#x02013;219</td><td align="left" rowspan="1" colspan="1">241&#x02013;250</td><td align="left" rowspan="1" colspan="1">241&#x02013;250</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt107"><p>The range of numbers listed below the region names are the amino acid locations covered by that region. Note that Minimum Entropy and Maximum Marginal Hyperplane were control active learning methods designed to work particularly poorly. More details are available in the supporting information <xref ref-type="supplementary-material" rid="pcbi.1000498.s002">Table S1</xref>.</p></fn></table-wrap-foot></table-wrap><p>Minimum Entropy and Maximum Marginal Hyperplane are versions of Maximum Entropy and Minimum Marginal Hyperplane (repectively) designed to do poorly, as negative controls. Indeed, the Negative Region chosen by Minimum Entropy overlaps nine of ten residues with the Positive Region chosen by Minimum Marginal Hyperplane. Similarly the Negative Region chosen by Maximum Marginal Hyperplane overlaps eight of ten residues with the Positive Region chosen by Maximum Entropy.</p><p>One might wonder if the classifier would have found the Expert region as a Positive Region in future experiments. <xref ref-type="fig" rid="pcbi-1000498-g005">Figure 5</xref> indicates the next Positive regions that would be selected, after the mutants found in the current Positive, Negative, and non-MIP regions, but not the Expert region, were added to the training set. There, the most informative positive mutants were found in the region from 130&#x02013;156, but the region 103&#x02013;119 also scored well, overlapping the Expert Region (114&#x02013;123). This is somewhat surprising as the classifier does not consider the Expert criteria, i.e., whether or not this residue appeared in a rescue mutant previously.</p><fig id="pcbi-1000498-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000498.g005</object-id><label>Figure 5</label><caption><title>New scores for Positive Regions using new data from the non-expert regions.</title><p>The score at each residue is the average Additive Curiosity score for those mutants predicted to be Positive for the preceding ten residues. The classifier here was trained with the original 463 mutants used in <xref ref-type="fig" rid="pcbi-1000498-g004">Figure 4</xref>, all Positive cancer rescue mutants found in the Positive, Negative, and non-MIP Regions, and all mutants from those three regions that were not Positive labeled as Negative. The vertical lines show the original Expert Region from residues 114&#x02013;123.</p></caption><graphic xlink:href="pcbi.1000498.g005"/></fig></sec><sec id="s3e"><title>Visualizations of Results</title><p>To better understand the regions selected and their relationship to the p53 protein, it is helpful to consider molecular visualizations of p53. Here, p53 is visualized with UCSF Chimera <xref ref-type="bibr" rid="pcbi.1000498-Cho1">&#x0005b;33&#x0005d;</xref>,<xref ref-type="bibr" rid="pcbi.1000498-Pettersen1">&#x0005b;42&#x0005d;</xref>. <xref ref-type="fig" rid="pcbi-1000498-g006">Figure 6</xref> presents a visualization of the Positive, Negative, non-MIP, and Expert regions on the p53 core domain. It is noteworthy that all of the regions selected in this study appear near the surface of the p53 molecule even though that was not explicitly a criterion in their selection. <xref ref-type="fig" rid="pcbi-1000498-g007">Figure 7</xref> shows the surface residues selected by the mutual information algorithm <xref ref-type="bibr" rid="pcbi.1000498-Francois1">&#x0005b;36&#x0005d;</xref> to be significant in determining the activity of p53 mutants <xref ref-type="bibr" rid="pcbi.1000498-Petitjean1">&#x0005b;12&#x0005d;</xref>. <xref ref-type="fig" rid="pcbi-1000498-g008">Figure 8</xref> shows all known single amino acid rescue mutations. <xref ref-type="fig" rid="pcbi-1000498-g009">Figure 9</xref> shows the 10 cancer mutants presented in <xref ref-type="table" rid="pcbi-1000498-t006">Table 6</xref>, <xref ref-type="fig" rid="pcbi-1000498-g010">Figure 10</xref> including the newly rescued P152L. <xref ref-type="fig" rid="pcbi-1000498-g010">Figure 10</xref> shows a different visualization of <xref ref-type="fig" rid="pcbi-1000498-g007">Figure 7</xref>.</p><fig id="pcbi-1000498-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000498.g006</object-id><label>Figure 6</label><caption><title>The four p53 regions visualized with the UCSF Chimera package.</title><p>The blue atoms near the DNA are the Expert Region, the red atoms near the top are the Negative and non-MIP Regions, and the green atoms near the bottom right are the Positive Region.</p></caption><graphic xlink:href="pcbi.1000498.g006"/></fig><fig id="pcbi-1000498-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000498.g007</object-id><label>Figure 7</label><caption><title>Surface residues selected by mutual information.</title><p>The blue atoms are those on the p53 surface ranked in the top 50 by the mutual information algorithm as influential on determining classifier accuracy.</p></caption><graphic xlink:href="pcbi.1000498.g007"/></fig><fig id="pcbi-1000498-g008" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000498.g008</object-id><label>Figure 8</label><caption><title>Single cancer rescue mutations.</title><p>The green atoms clustered mostly in the center of p53 are single amino acid cancer rescue mutations. The blue atoms, such as those on the left and in the lower right corner, are those single cancer rescue mutations that are also selected by mutual information as shown in <xref ref-type="fig" rid="pcbi-1000498-g007">Figure 7</xref>.</p></caption><graphic xlink:href="pcbi.1000498.g008"/></fig><fig id="pcbi-1000498-g009" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000498.g009</object-id><label>Figure 9</label><caption><title>The ten p53 cancer mutants studied here.</title><p>The red atoms clustered primarily near the top left are those cancer mutations that are currently unrescuable. The green atoms clustered primarily near the lower left are the rescuable cancer mutations. The yellow atoms near the right are the newly rescued P152 mutation.</p></caption><graphic xlink:href="pcbi.1000498.g009"/></fig><fig id="pcbi-1000498-g010" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000498.g010</object-id><label>Figure 10</label><caption><title>Rescue by p53 surface residues.</title><p>The above visualization is the same as <xref ref-type="fig" rid="pcbi-1000498-g009">Figure 9</xref> but rotated and with the surface displayed.</p></caption><graphic xlink:href="pcbi.1000498.g010"/></fig></sec></sec><sec id="s4"><title>Discussion</title><p>This paper introduced Most Informative Positive (MIP) active learning, based on machine learning techniques and modeled structure-based features, to help guide biological experiments. The method discovered novel and informative positive results.</p><sec id="s4a"><title>Medical Significance of the Data Set</title><p>The ten different cancer mutants studied here account for about one million diagnosed cancers per year. The rescue of cancer mutant P152L by a mutation in the Positive Region is the first report that this common cancer mutant can be rescued at all.</p><p>The <italic>in silico</italic> identification and biological verification of a new cancer rescue region is a small but hopefully useful step towards selection of p53 surface regions that potentially result in p53 cancer rescue when appropriately modified. Such regions eventually might be targeted by small molecule drugs. For example, <xref ref-type="fig" rid="pcbi-1000498-g010">Figure 10</xref> shows an area on the surface of the p53 core domain that is: (1) away from the DNA binding region; (2) overlapping or adjacent to the Positive Region; (3) implicated by mutual information as influential in determining p53 activity; and (4) located where structural changes restore functional activity to some cancerous p53 mutants. Better knowledge of p53 mutant structure-function relationships eventually might lead to successful pharmaceutical manipulation of p53 mutant function.</p><p>It has been hypothesized that different p53 cancer rescue mutants have different rescue mechanisms corresponding to different types of cancer mutations <xref ref-type="bibr" rid="pcbi.1000498-Bullock1">&#x0005b;22&#x0005d;</xref>,<xref ref-type="bibr" rid="pcbi.1000498-Martin1">&#x0005b;25&#x0005d;</xref>. For example, the Expert Region rescued the more frequent p53 cancer mutant G245S while the Positive Region did not. Conversely, the Positive Region is unique in its ability to rescue the P152L mutant. Different rescue regions may implement different rescue mechanisms, and so contribute different facets to knowledge of cancer rescue.</p></sec><sec id="s4b"><title>Extensions</title><p>From <xref ref-type="fig" rid="pcbi-1000498-g004">Figure 4</xref>, the Expert Region had both low average curiosity (.462) and relatively few (34) mutants predicted Positive. Thus, this region was not selected by the classifier, yet a significant number of rescue mutants were identified in this region. This is not surprising, as the classifier was not directly exposed to the criteria used for selecting the Expert Region. Conversely, it is not surprising that an expert cancer biologist could pick a fruitful region for reasons unknown to the classifier. Adding expert-level knowledge to a performance system is a long-time success story of artificial intelligence <xref ref-type="bibr" rid="pcbi.1000498-Buchanan1">&#x0005b;43&#x0005d;</xref>. Integrating diverse expert sources and methods using bioinformatics leads to biomedical discovery acceleration <xref ref-type="bibr" rid="pcbi.1000498-Leach1">&#x0005b;44&#x0005d;</xref>. Adding new features that encode expert or literature knowledge directly into the feature vector that encodes each example is one simple way to make expert knowledge visible to any feature-based learning system.</p><p>Similarly, the classifier does not now weigh the medical impact of different p53 cancer mutants. Cancer mutation occurrence frequencies were not given to the classifier, so it is not surprising that it rescued a less frequent cancer mutant than did the expert. Weighting by cancer mutation frequency, or by any other desired utility function, is one simple way to implement a selection preference for some informative Positives over others.</p></sec><sec id="s4c"><title>Conclusion</title><p>MIP active learning using modeled structural features was introduced and shown to be a useful framework for function-based biological research. It provided an analysis tool yielding results that otherwise would have been unexpected or unavailable.</p><p>From the perspective of a biologist, the computer-selected Positive Region would not have been chosen as a potential region for cancer rescue: It did not contain any known cancer rescue mutants, and none of the random biology-based approaches had ever identified rescue activity in this region. This result provides a proof-of-concept that a computational classifier and modeled structure-based features can provide insight to help guide function-based experimental discovery.</p></sec><sec id="s4d"><title>Availability</title><p>All code and data used in this paper is freely available online at <ext-link ext-link-type="uri" xlink:href="https://sourceforge.net/projects/p53cancerrescue/files/">https://sourceforge.net/projects/p53cancerrescue/files/</ext-link>. The data is also available in <xref ref-type="supplementary-material" rid="pcbi.1000498.s001">Dataset S1</xref>.</p><p>All mutant DNA vectors are available under standard material transfer agreements through the UCI Office of Technology Alliances (<ext-link ext-link-type="uri" xlink:href="http://www.ota.uci.edu/">http://www.ota.uci.edu/</ext-link>).</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pcbi.1000498.s001"><label>Dataset S1</label><caption><p>The raw curiosity scores used to generate <xref ref-type="fig" rid="pcbi-1000498-g003">Figures 3</xref> &#x00026; <xref ref-type="fig" rid="pcbi-1000498-g005">5</xref> and select the regions shown <xref ref-type="table" rid="pcbi-1000498-t007">Table 7</xref>.</p><p>(2.17 MB ZIP)</p></caption><media xlink:href="pcbi.1000498.s001.zip" mimetype="application" mime-subtype="x-zip-compressed"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1000498.s002"><label>Table S1</label><caption><p><xref ref-type="table" rid="pcbi-1000498-t007">Table 7</xref> - Region Selection by Active Learning Algorithms as dynamically generated by Microsoft Excel. Intended for use with <xref ref-type="supplementary-material" rid="pcbi.1000498.s001">Dataset S1</xref>.</p><p>(0.23 MB XLS)</p></caption><media xlink:href="pcbi.1000498.s002.xlsx" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1000498.s003"><label>Text S1</label><caption><p>Active Learning Related Symbols</p><p>(0.06 MB DOC)</p></caption><media xlink:href="pcbi.1000498.s003.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>Thanks to Amanda Danziger for graphical design services, Dr. Rainer K. Brachmann for suggesting the Expert Region, and the blind reviewers for helpful improvements.</p></ack><ref-list><title>References</title><ref id="pcbi.1000498-Fersht1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fersht</surname><given-names>AR</given-names></name><name><surname>Matouschek</surname><given-names>A</given-names></name><name><surname>Serrano</surname><given-names>L</given-names></name></person-group><year>1992</year><article-title>The folding of an enzyme. I. Theory of protein engineering analysis of stability and pathway of protein folding.</article-title><source>J Mol Biol</source><volume>224</volume><fpage>771</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">1569556</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Huston1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huston</surname><given-names>JS</given-names></name><name><surname>Levinson</surname><given-names>D</given-names></name><name><surname>Mudgett-Hunter</surname><given-names>M</given-names></name><name><surname>Tai</surname><given-names>MS</given-names></name><name><surname>Novotny</surname><given-names>J</given-names></name><etal/></person-group><year>1988</year><article-title>Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.</article-title><source>Proc Natl Acad Sci U S A</source><volume>85</volume><fpage>5879</fpage><lpage>5883</lpage><pub-id pub-id-type="pmid">3045807</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Danziger1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danziger</surname><given-names>SA</given-names></name><name><surname>Swamidass</surname><given-names>SJ</given-names></name><name><surname>Zeng</surname><given-names>J</given-names></name><name><surname>Dearth</surname><given-names>LR</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><etal/></person-group><year>2006</year><article-title>Functional census of mutation sequence spaces: the example of p53 cancer rescue mutants.</article-title><source>IEEE/ACM Trans Comput Biol Bioinform</source><volume>3</volume><fpage>114</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">17048398</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Danziger2"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danziger</surname><given-names>SA</given-names></name><name><surname>Zeng</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Brachmann</surname><given-names>RK</given-names></name><name><surname>Lathrop</surname><given-names>RH</given-names></name></person-group><year>2007</year><article-title>Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants.</article-title><source>Bioinformatics</source><volume>23</volume><fpage>i104</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">17646286</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Fox1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>RJ</given-names></name><name><surname>Huisman</surname><given-names>GW</given-names></name></person-group><year>2008</year><article-title>Enzyme optimization: moving from blind evolution to statistical exploration of sequence-function space.</article-title><source>Trends Biotechnol</source><volume>26</volume><fpage>132</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">18222559</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Karaguler1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karaguler</surname><given-names>NG</given-names></name><name><surname>Sessions</surname><given-names>RB</given-names></name><name><surname>Binay</surname><given-names>B</given-names></name><name><surname>Ordu</surname><given-names>EB</given-names></name><name><surname>Clarke</surname><given-names>AR</given-names></name></person-group><year>2007</year><article-title>Protein engineering applications of industrially exploitable enzymes: Geobacillus stearothermophilus LDH and Candida methylica FDH.</article-title><source>Biochem Soc Trans</source><volume>35</volume><fpage>1610</fpage><lpage>1615</lpage><pub-id pub-id-type="pmid">18031276</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Nikolova1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolova</surname><given-names>PV</given-names></name><name><surname>Henckel</surname><given-names>J</given-names></name><name><surname>Lane</surname><given-names>DP</given-names></name><name><surname>Fersht</surname><given-names>AR</given-names></name></person-group><year>1998</year><article-title>Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability.</article-title><source>Proc Natl Acad Sci U S A</source><volume>95</volume><fpage>14675</fpage><lpage>14680</lpage><pub-id pub-id-type="pmid">9843948</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Dantas1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dantas</surname><given-names>G</given-names></name><name><surname>Corrent</surname><given-names>C</given-names></name><name><surname>Reichow</surname><given-names>SL</given-names></name><name><surname>Havranek</surname><given-names>JJ</given-names></name><name><surname>Eletr</surname><given-names>ZM</given-names></name><etal/></person-group><year>2007</year><article-title>High-resolution structural and thermodynamic analysis of extreme stabilization of human procarboxypeptidase by computational protein design.</article-title><source>J Mol Biol</source><volume>366</volume><fpage>1209</fpage><lpage>1221</lpage><pub-id pub-id-type="pmid">17196978</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Brooks1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>CL</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name></person-group><year>2008</year><article-title>p53 Activation: a case against Sir.</article-title><source>Cancer Cell</source><volume>13</volume><fpage>377</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">18455119</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Hollstein1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollstein</surname><given-names>M</given-names></name><name><surname>Sidransky</surname><given-names>D</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Harris</surname><given-names>CC</given-names></name></person-group><year>1991</year><article-title>p53 mutations in human cancers.</article-title><source>Science</source><volume>253</volume><fpage>49</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">1905840</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Kato1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>SY</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Otsuka</surname><given-names>K</given-names></name><name><surname>Shibata</surname><given-names>H</given-names></name><etal/></person-group><year>2003</year><article-title>Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.</article-title><source>Proc Natl Acad Sci U S A</source><volume>100</volume><fpage>8424</fpage><lpage>8429</lpage><pub-id pub-id-type="pmid">12826609</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Petitjean1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petitjean</surname><given-names>A</given-names></name><name><surname>Mathe</surname><given-names>E</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name><name><surname>Ishioka</surname><given-names>C</given-names></name><name><surname>Tavtigian</surname><given-names>SV</given-names></name><etal/></person-group><year>2007</year><article-title>Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.</article-title><source>Hum Mutat</source><volume>28</volume><fpage>622</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">17311302</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Baroni1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baroni</surname><given-names>TE</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Qian</surname><given-names>H</given-names></name><name><surname>Dearth</surname><given-names>LR</given-names></name><name><surname>Truong</surname><given-names>LN</given-names></name><etal/></person-group><year>2004</year><article-title>A global suppressor motif for p53 cancer mutants.</article-title><source>Proc Natl Acad Sci U S A</source><volume>101</volume><fpage>4930</fpage><lpage>4935</lpage><pub-id pub-id-type="pmid">15037740</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Brachmann1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brachmann</surname><given-names>RK</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Eby</surname><given-names>Y</given-names></name><name><surname>Pavletich</surname><given-names>NP</given-names></name><name><surname>Boeke</surname><given-names>JD</given-names></name></person-group><year>1998</year><article-title>Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations.</article-title><source>Embo J</source><volume>17</volume><fpage>1847</fpage><lpage>1859</lpage><pub-id pub-id-type="pmid">9524109</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Otsuka1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otsuka</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name><name><surname>Kakudo</surname><given-names>Y</given-names></name><name><surname>Mashiko</surname><given-names>S</given-names></name><name><surname>Shibata</surname><given-names>H</given-names></name><etal/></person-group><year>2007</year><article-title>The screening of the second-site suppressor mutations of the common p53 mutants.</article-title><source>Int J Cancer</source><volume>121</volume><fpage>559</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">17417775</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Sharpless1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharpless</surname><given-names>NE</given-names></name><name><surname>DePinho</surname><given-names>RA</given-names></name></person-group><year>2007</year><article-title>Cancer biology: gone but not forgotten.</article-title><source>Nature</source><volume>445</volume><fpage>606</fpage><lpage>607</lpage><pub-id pub-id-type="pmid">17251931</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Ventura1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ventura</surname><given-names>A</given-names></name><name><surname>Kirsch</surname><given-names>DG</given-names></name><name><surname>McLaughlin</surname><given-names>ME</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name><name><surname>Grimm</surname><given-names>J</given-names></name><etal/></person-group><year>2007</year><article-title>Restoration of p53 function leads to tumour regression in vivo.</article-title><source>Nature</source><volume>445</volume><fpage>661</fpage><lpage>665</lpage><pub-id pub-id-type="pmid">17251932</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Xue1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>W</given-names></name><name><surname>Zender</surname><given-names>L</given-names></name><name><surname>Miething</surname><given-names>C</given-names></name><name><surname>Dickins</surname><given-names>RA</given-names></name><name><surname>Hernando</surname><given-names>E</given-names></name><etal/></person-group><year>2007</year><article-title>Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.</article-title><source>Nature</source><volume>445</volume><fpage>656</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">17251933</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Lain1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lain</surname><given-names>S</given-names></name><name><surname>Hollick</surname><given-names>JJ</given-names></name><name><surname>Campbell</surname><given-names>J</given-names></name><name><surname>Staples</surname><given-names>OD</given-names></name><name><surname>Higgins</surname><given-names>M</given-names></name><etal/></person-group><year>2008</year><article-title>Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.</article-title><source>Cancer Cell</source><volume>13</volume><fpage>454</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">18455128</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Bykov1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bykov</surname><given-names>VJ</given-names></name><name><surname>Selivanova</surname><given-names>G</given-names></name><name><surname>Wiman</surname><given-names>KG</given-names></name></person-group><year>2003</year><article-title>Small molecules that reactivate mutant p53.</article-title><source>Eur J Cancer</source><volume>39</volume><fpage>1828</fpage><lpage>1834</lpage><pub-id pub-id-type="pmid">12932659</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Wang1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Rastinejad</surname><given-names>F</given-names></name><name><surname>El-Deiry</surname><given-names>WS</given-names></name></person-group><year>2003</year><article-title>Restoring p53-dependent tumor suppression.</article-title><source>Cancer Biol Ther</source><volume>2</volume><fpage>S55</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">14508081</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Bullock1"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullock</surname><given-names>AN</given-names></name><name><surname>Fersht</surname><given-names>AR</given-names></name></person-group><year>2001</year><article-title>Rescuing the function of mutant p53.</article-title><source>Nat Rev Cancer</source><volume>1</volume><fpage>68</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">11900253</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Brachmann2"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brachmann</surname><given-names>RK</given-names></name></person-group><year>2004</year><article-title>p53 mutants: the achilles' heel of human cancers?</article-title><source>Cell Cycle</source><volume>3</volume><fpage>1030</fpage><lpage>1034</lpage><pub-id pub-id-type="pmid">15280671</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Lambert1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>JM</given-names></name><name><surname>Gorzov</surname><given-names>P</given-names></name><name><surname>Veprintsev</surname><given-names>DB</given-names></name><name><surname>Soderqvist</surname><given-names>M</given-names></name><name><surname>Segerback</surname><given-names>D</given-names></name><etal/></person-group><year>2009</year><article-title>PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.</article-title><source>Cancer Cell</source><volume>15</volume><fpage>376</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">19411067</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Martin1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>AC</given-names></name><name><surname>Facchiano</surname><given-names>AM</given-names></name><name><surname>Cuff</surname><given-names>AL</given-names></name><name><surname>Hernandez-Boussard</surname><given-names>T</given-names></name><name><surname>Olivier</surname><given-names>M</given-names></name><etal/></person-group><year>2002</year><article-title>Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein.</article-title><source>Hum Mutat</source><volume>19</volume><fpage>149</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">11793474</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Joerger1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joerger</surname><given-names>AC</given-names></name><name><surname>Ang</surname><given-names>HC</given-names></name><name><surname>Veprintsev</surname><given-names>DB</given-names></name><name><surname>Blair</surname><given-names>CM</given-names></name><name><surname>Fersht</surname><given-names>AR</given-names></name></person-group><year>2005</year><article-title>Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations.</article-title><source>J Biol Chem</source><volume>280</volume><fpage>16030</fpage><lpage>16037</lpage><pub-id pub-id-type="pmid">15703170</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Glaser1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glaser</surname><given-names>F</given-names></name><name><surname>Morris</surname><given-names>RJ</given-names></name><name><surname>Najmanovich</surname><given-names>RJ</given-names></name><name><surname>Laskowski</surname><given-names>RA</given-names></name><name><surname>Thornton</surname><given-names>JM</given-names></name></person-group><year>2006</year><article-title>A method for localizing ligand binding pockets in protein structures.</article-title><source>Proteins</source><volume>62</volume><fpage>479</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">16304646</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Cuff1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuff</surname><given-names>AL</given-names></name><name><surname>Martin</surname><given-names>AC</given-names></name></person-group><year>2004</year><article-title>Analysis of void volumes in proteins and application to stability of the p53 tumour suppressor protein.</article-title><source>J Mol Biol</source><volume>344</volume><fpage>1199</fpage><lpage>1209</lpage><pub-id pub-id-type="pmid">15561139</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Cohn1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohn</surname><given-names>DA</given-names></name><name><surname>Ghahramani</surname><given-names>Z</given-names></name><name><surname>Jordan</surname><given-names>MI</given-names></name></person-group><year>1996</year><article-title>Active Learning with Statistical Models.</article-title><source>Journal of Artificial Intelligence Research</source><volume>4</volume><fpage>129</fpage><lpage>145</lpage></mixed-citation></ref><ref id="pcbi.1000498-SaarTsechansky1"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saar-Tsechansky</surname><given-names>M</given-names></name><name><surname>Provost</surname><given-names>F</given-names></name></person-group><year>2004</year><article-title>Active Sampling for Class Probability Estimation and Ranking.</article-title><source>Machine Learning</source><volume>54</volume><fpage>153</fpage><lpage>178</lpage></mixed-citation></ref><ref id="pcbi.1000498-Jones1"><label>31</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>R</given-names></name><name><surname>Ghani</surname><given-names>R</given-names></name><name><surname>Mitchell</surname><given-names>T</given-names></name><name><surname>Riloff</surname><given-names>E</given-names></name></person-group><year>2003</year><article-title>Active learning for information extraction with multiple view feature sets.</article-title><comment>Proceedings of the ECML-2004 Workshop on Adaptive Text Extraction and Mining (ATEM-2003)</comment></mixed-citation></ref><ref id="pcbi.1000498-Roy1"><label>32</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>N</given-names></name><name><surname>McCallum</surname><given-names>A</given-names></name></person-group><year>2001</year><article-title>Toward Optimal Active Learning through Sampling Estimation of Error Reduction.</article-title><fpage>441</fpage><lpage>448</lpage><comment>Proceedings of the Eighteenth International Conference on Machine Learning</comment></mixed-citation></ref><ref id="pcbi.1000498-Cho1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>Y</given-names></name><name><surname>Gorina</surname><given-names>S</given-names></name><name><surname>Jeffrey</surname><given-names>PD</given-names></name><name><surname>Pavletich</surname><given-names>NP</given-names></name></person-group><year>1994</year><article-title>Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.</article-title><source>Science</source><volume>265</volume><fpage>346</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">8023157</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Case1"><label>34</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Case</surname><given-names>DA</given-names></name><name><surname>Darden</surname><given-names>TA</given-names></name><name><surname>Cheatham</surname><given-names>TE</given-names><suffix>I</suffix></name><name><surname>Simmerling</surname><given-names>CL</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><year>2008</year><comment>Amber 10</comment></mixed-citation></ref><ref id="pcbi.1000498-Friedler1"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedler</surname><given-names>A</given-names></name><name><surname>Veprintsev</surname><given-names>DB</given-names></name><name><surname>Rutherford</surname><given-names>T</given-names></name><name><surname>von Glos</surname><given-names>KI</given-names></name><name><surname>Fersht</surname><given-names>AR</given-names></name></person-group><year>2005</year><article-title>Binding of Rad51 and other peptide sequences to a promiscuous, highly electrostatic binding site in p53.</article-title><source>J Biol Chem</source><volume>280</volume><fpage>8051</fpage><lpage>8059</lpage><pub-id pub-id-type="pmid">15611070</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Francois1"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francois</surname><given-names>F</given-names></name></person-group><year>2004</year><article-title>Fast Binary Feature Selection with Conditional Mutual Information.</article-title><source>J Mach Learn Res</source><volume>5</volume><fpage>1531</fpage><lpage>1555</lpage></mixed-citation></ref><ref id="pcbi.1000498-Hearst1"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hearst</surname><given-names>MA</given-names></name><name><surname>Dumais</surname><given-names>ST</given-names></name><name><surname>Osman</surname><given-names>E</given-names></name><name><surname>Platt</surname><given-names>J</given-names></name><name><surname>Scholkopf</surname><given-names>B</given-names></name></person-group><year>1998</year><article-title>Support vector machines.</article-title><source>IEEE Transactions on Intelligent Systems and their Applications</source><volume>13</volume><fpage>18</fpage><lpage>28</lpage></mixed-citation></ref><ref id="pcbi.1000498-Feng1"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Mingjing</surname><given-names>L</given-names></name><name><surname>Hong-Jiang</surname><given-names>Z</given-names></name><name><surname>Bo</surname><given-names>Z</given-names></name></person-group><year>2005</year><article-title>A unified framework for image retrieval using keyword and visual features.</article-title><source>IEEE Transactions on Image Processing</source><volume>14</volume><fpage>979</fpage><lpage>989</lpage><pub-id pub-id-type="pmid">16028561</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Itti1"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itti</surname><given-names>L</given-names></name><name><surname>Baldi</surname><given-names>P</given-names></name></person-group><year>2009</year><article-title>Bayesian surprise attracts human attention.</article-title><source>Vision Res</source><volume>49</volume><fpage>1295</fpage><lpage>1306</lpage><pub-id pub-id-type="pmid">18834898</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Baldi1"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldi</surname><given-names>P</given-names></name><name><surname>Brunak</surname><given-names>S</given-names></name><name><surname>Chauvin</surname><given-names>Y</given-names></name><name><surname>Andersen</surname><given-names>CAF</given-names></name><name><surname>Nielsen</surname><given-names>H</given-names></name></person-group><year>2000</year><article-title>Assessing the accuracy of prediction algorithms for classification: an overview.</article-title><source>Bioinformatics</source><volume>16</volume><fpage>412</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">10871264</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Witten1"><label>41</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Witten</surname><given-names>IH</given-names></name><name><surname>Frank</surname><given-names>E</given-names></name></person-group><year>2005</year><article-title>Data mining: practical machine learning tools and techniques.</article-title><publisher-loc>Amsterdam; Boston, MA</publisher-loc><publisher-name>Morgan Kaufman</publisher-name><size units="page"/></mixed-citation></ref><ref id="pcbi.1000498-Pettersen1"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><name><surname>Goddard</surname><given-names>TD</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Couch</surname><given-names>GS</given-names></name><name><surname>Greenblatt</surname><given-names>DM</given-names></name><etal/></person-group><year>2004</year><article-title>UCSF Chimera&#x02013;a visualization system for exploratory research and analysis.</article-title><source>J Comput Chem</source><volume>25</volume><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="pmid">15264254</pub-id></mixed-citation></ref><ref id="pcbi.1000498-Buchanan1"><label>43</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Buchanan</surname><given-names>BG</given-names></name><name><surname>Shortliffe</surname><given-names>EH</given-names></name></person-group><year>1984</year><article-title>Rule Based Expert Systems: The Mycin Experi-ments of the Stanford Heuristic Programming Project.</article-title><publisher-loc>Boston, MA</publisher-loc><publisher-name>Addison-Wesley Longman Publishing Co., Inc</publisher-name></mixed-citation></ref><ref id="pcbi.1000498-Leach1"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leach</surname><given-names>SM</given-names></name><name><surname>Tipney</surname><given-names>H</given-names></name><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Baumgartner</surname><given-names>WA</given-names></name><name><surname>Kasliwal</surname><given-names>P</given-names></name><etal/></person-group><year>2009</year><article-title>Biomedical discovery acceleration, with applications to craniofacial development.</article-title><source>PLoS Comput Biol</source><volume>5</volume><fpage>e1000215</fpage><pub-id pub-id-type="pmid">19325874</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p>This work was supported in part by the National Institute of Health (NIH) Biomedical Informatics Training grant &#x0005b;grant number LM-07443&#x0005d; to SD, the NIH BISTI grant &#x0005b;grant number CA-112560&#x0005d;, and the NSF &#x0005b;grant number IIS-0326037&#x0005d;. URL: <ext-link ext-link-type="uri" xlink:href="http://nih.gov/">http://nih.gov/</ext-link>. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>